Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05790564
Other study ID # LPI-2022-1435
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 17, 2022
Est. completion date July 2025

Study information

Verified date March 2023
Source Oregon State University
Contact Laura Beaver, PhD
Phone 541-737-5049
Email laura.beaver@oregonstate.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Almonds are a good source of beneficial compounds. This study will investigate if eating almonds everyday for 12 weeks can affect gut health and inflammation in persons with metabolic syndrome. Investigators will measure changes in metabolism, heart health, and the levels of vitamins and other compounds from almonds.


Description:

Metabolic Syndrome (MetS) affects over a billion people world-wide. MetS progression and further health complications are driven by chronic inflammation. Major causes of inflammation in MetS are gut barrier breakdown and the absorption of harmful bacteria. What causes the gut barrier breakdown is not clear, but a poor diet, especially low micronutrient intakes like vitamin E, is implicated by propagating a vicious cycle that promotes oxidative stress, inflammation and further gut barrier damage. This study will assess the impact of daily consumption of 2 ounces of almonds for 12 weeks on gut health, markers of inflammation and cardiometabolic health, and micronutrient status in persons with MetS.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date July 2025
Est. primary completion date September 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 60 Years
Eligibility Inclusion Criteria: - Age 35-60 years - 3 or more of the following: hypertension (systolic BP 130-179 mmHg or diastolic BP 85-119 mmHg); hyperglycemia (fasting glucose 100-599 mg/dL); central obesity [waist circumference greater than 40.1 inches (M) or 34.6 inches (F); hypertriglyceridemia (150-499 mg/dL); low HDL [lower than 40 mg/dL (M) or 50 mg/dL (F)] - Willing to restrict consumption of nuts other than study nuts for 1 week prior to and throughout the study (13 weeks) - Willing to stop probiotic supplements one week prior to and during the study (13 weeks) - Willing to stop multivitamins and supplements containing vitamin E, magnesium, calcium, iron, zinc and copper one week prior to and during the study (13 weeks) - Willing to complete intake diaries during the study - Willing to maintain current eating patterns (no significant diet change during study) Exclusion Criteria: - Weekly consumption of almonds, hazelnuts, peanuts and sunflower seeds combined greater than 2 servings (about 2 oz) in the past 3 months - Nut, wheat, or gluten allergy/intolerance - Regular use of vitamin E supplements - Consume more than 2 alcoholic drinks daily - Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past 3 months - Pregnancy, breastfeeding, or planning to become pregnant before completing the study - Vigorous exercise greater than 7 hours/week - History of cardiovascular disease, liver disease or cancer - Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedures (e.g. cholecystectomy), disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis) or chronic diarrhea - Diagnosis of hemochromatosis - Chronic use (daily intake in past 30 days) of anti-inflammatory medication (steroid or NSAID) - Use of ezetimibe or orlistat - Use of oral antibiotic medication within the past month - Body Mass Index (BMI) <25.0 or >35.0 kg/m2 - Regular use of multivitamin supplements in the past 3 months - Physician prescribed use of probiotic, vitamin E, magnesium, calcium, iron, zinc or copper supplements

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Almond
Daily consumption of 2 ounces of unsalted, dry roasted almonds for 12 weeks
Crackers
Daily consumption of non-whole grain crackers for 12 weeks (caloric equivalent to 2 ounces of dry roasted almonds)

Locations

Country Name City State
United States Oregon State University Corvallis Oregon

Sponsors (1)

Lead Sponsor Collaborator
Oregon State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gut permeability and health: Serum endotoxin Change from baseline at week 4: Marker of gut barrier function and health, serum endotoxin 0 and 4 weeks
Primary Gut permeability and health: Short chain fatty acids Change from baseline at week 4: Markers of gut barrier function and health fecal short chain fatty acids profiles 0 and 4 weeks
Primary Gut permeability and health: Inflammatory biomarkers Change from baseline at week 4: Gut inflammatory biomarkers calprotectin and myeloperoxidase 0 and 4 weeks
Primary Biomarkers of inflammation Change from baseline at week 4: Plasma inflammatory markers (ex. TNF and IL-6) 0 and 4 weeks
Primary Oxidative stress status: malondialdehyde Change from baseline at week 4: Plasma malondialdehyde 0 and 4 weeks
Primary Oxidative stress status: isoprostanes Change from baseline at week 4: Urinary isoprostanes 0 and 4 weeks
Primary Cardiometabolic health Change from baseline at week 12: Total cholesterol, LDL, HDL, and triglycerides 0 and 12 weeks
Primary Vitamin E status Change from baseline at week 4 and week 12: Plasma a-tocopherols 0, 4 and 12 weeks
Primary Vitamin E status: Urinary catabolite Change from baseline at week 4 and week 12: Urinary vitamin E catabolite (a-CEHC) 0, 4 and 12 weeks
Secondary Blood pressure Change from baseline at week 4 and week 12: Systolic, and diastolic blood pressure 0, 4 and 12 weeks
Secondary Weight Change from baseline at week 4 and week 12: Weight 0, 4 and 12 weeks
Secondary BMI Change from baseline at week 4 and week 12: BMI (weight and height will be combined to report BMI in kg/m^2) 0, 4 and 12 weeks
Secondary Waist circumference Change from baseline at week 4 and week 12: Waist circumference 0, 4 and 12 weeks
Secondary Glycemic control: glucose Change from baseline at week 12: Fasting blood glucose 0 and 12 weeks
Secondary Glycemic control: Insulin Change from baseline at week 12: Insulin 0 and 12 weeks
Secondary Glycemic control: HOMA-IR Change from baseline at week 12: HOMA-IR 0 and 12 weeks
Secondary Other almond-based bioactives (polyphenol levels) Change from baseline at week 12: Urinary metabolites of flavonoids like (+)-catechin, (-)-epicatechin and naringenin 0 and 12 weeks
Secondary Mineral status Change from baseline at week 12: Plasma magnesium, calcium, iron, zinc, and copper (microgram/mL) 0 and 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04635202 - Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome N/A
Completed NCT05343858 - Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome N/A
Completed NCT04053686 - An Intervention to Reduce Prolonged Sitting in Police Staff N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Recruiting NCT05040958 - Carotid Atherosclerotic Plaque Load and Neck Circumference
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT06057896 - Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
Active, not recruiting NCT03613740 - Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Phase 2
Completed NCT04498455 - Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency Phase 4
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT04509206 - Virtual Teaching Kitchen N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A